The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease

Clinical trial NCT06975865 · RECRUITING

Trial details

NCT number: NCT06975865
Sponsor: Sanofi
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Sickle Cell Disease

Start date: 2025-08-12
Primary completion: 2027-07-23
Enrollment: 192

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.